Search
Potassium perchlorate
go.drugbank.com/drugs/DB09418ApprovedWithdrawnPotassium is most commonly used in flares and automobile airbags [A32609]. … Potassium perchlorate is an inorganic salt with the chemical formula KClO4. It is a strong oxidizer with the lowest solubility of the alkali metal perchlorates.
Doxylamine
go.drugbank.com/drugs/DB00366ApprovedInvestigationalVet approvedIt is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism.
Mixtures: N - Time, N - Time SinusSynonyms: N,N-Dimethyl-2-(1-phenyl-1-(2-pyridinyl)ethoxy)ethanamine, Phenyl-2-pyridylmethyl-beta-N,N-dimethylaminoethyl etherChromium picolinate
go.drugbank.com/drugs/DB11255ApprovedIt is a coordination complex consisting of chromium(III) and picolinic acid. … Chromium picolinate is used as a nutritional supplement for optimal insulin function in patients with Type 2 diabetes or promotion of weight loss.
Categories: Compounds used in a research, industrial, or household settingYellow fever vaccine
go.drugbank.com/drugs/DB10805ApprovedInvestigationalYellow Fever is most commonly found in the southern hemisphere, in tropical regions of Africa and Central/South America [L1653]. … Yellow fever vaccine prevents against Yellow Fever, a viral hemorrhagic disease caused by the transmission of a _flavivirus_ through the bite of an infected mosquito.
Categories: Complex MixturesBenzhydrocodone
go.drugbank.com/drugs/DB15465Approved[L4894] It was developed in an effort to reduce parenteral bioavailability of the active metabolite as a deterrent to abuse. … It was first approved by the FDA in February 2018 in combination with [acetaminophen] under the trade name Apadaz, marketed by KVK Tech and developed by KemPharm.[L7859,L7862]
Brexpiprazole
go.drugbank.com/drugs/DB09128ApprovedInvestigational[A182186, A38385, A259661] Brexpiprazole was first approved by the FDA on July 10, 2015. … Compared to aripiprazole, brexpiprazole has less potential for partial agonist-mediated adverse effects such as extrapyramidal symptoms, which is attributed to lower intrinsic activity at the D2 receptor
Vibegron
go.drugbank.com/drugs/DB14895ApprovedInvestigationalOn December 23, 2020, vibegron was approved for the same indication in adults. It is available as oral tablets under the market name GEMTESA. … [L28305] Vibegron was first approved in Japan in September 2018 for the treatment of overactive bladder,[A226050] a condition associated with distressing symptoms of urge urinary incontinence, urgency,
Pimozide
go.drugbank.com/drugs/DB01100ApprovedA diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome.
Delamanid
go.drugbank.com/drugs/DB11637ApprovedInvestigationalIt is used in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis (TB) in a combination regimen. … In a clinical study involving patients with pulmonary multidrug-resistant tuberculosis or extensively drug-resistant tuberculosis, treatment of delamanid in combination with WHO-recommended optimised background
Penbutolol
go.drugbank.com/drugs/DB01359ApprovedInvestigationalWithdrawnThis binding characteristic of penbutolol is being investigated for its implications in Antidepressant Therapy. … Penbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker.